(Total Views: 707)
Posted On: 01/04/2021 1:26:19 PM
Post# of 153930
Re: thriftycents #71200
ohms message on stocktwits
09:15 AM
@Darronm HGEN's lenzilumab is a GM-CSF inhibitor, CYDY's leromlimab downregulates GM-CSF, downregulates COVID's secondary receptor neuropilin-1, directly blocks chemokines stopping the cytokine storm, downregulates bradykinin, increases CD8+ T-cells which are what kills the virus, downregulates JAK1/2, stops hypercoagulopathy and potentially lowers viral reproduction through disruption of the mTORc-1 pathway
.
Ohm: Can you please comment on the following. Is the mTOR pathway similar to that of LL? My wife is about to be enrolled in an MSK cancer study that emphasizes the m-TOR pathway. TIA.
PACIFIC PALISADES, Calif.--(BUSINESS WIRE)--Aadi Bioscience, Inc. (Aadi), a privately held biopharmaceutical company focused on development and commercialization of nab-sirolimus (sirolimus albumin-bound nanoparticles for injectable suspension) in mTOR driven diseases,
https://www.businesswire.com/news/home/202006...ant-PEComa
09:15 AM
@Darronm HGEN's lenzilumab is a GM-CSF inhibitor, CYDY's leromlimab downregulates GM-CSF, downregulates COVID's secondary receptor neuropilin-1, directly blocks chemokines stopping the cytokine storm, downregulates bradykinin, increases CD8+ T-cells which are what kills the virus, downregulates JAK1/2, stops hypercoagulopathy and potentially lowers viral reproduction through disruption of the mTORc-1 pathway
.
Ohm: Can you please comment on the following. Is the mTOR pathway similar to that of LL? My wife is about to be enrolled in an MSK cancer study that emphasizes the m-TOR pathway. TIA.
PACIFIC PALISADES, Calif.--(BUSINESS WIRE)--Aadi Bioscience, Inc. (Aadi), a privately held biopharmaceutical company focused on development and commercialization of nab-sirolimus (sirolimus albumin-bound nanoparticles for injectable suspension) in mTOR driven diseases,
https://www.businesswire.com/news/home/202006...ant-PEComa
(1)
(0)
